215 related articles for article (PubMed ID: 12789171)
1. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis.
Gottlieb AB; Chaudhari U; Mulcahy LD; Li S; Dooley LT; Baker DG
J Am Acad Dermatol; 2003 Jun; 48(6):829-35. PubMed ID: 12789171
[TBL] [Abstract][Full Text] [Related]
2. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
3. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
5. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
8. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
12. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
13. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
16. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade)].
Valdés A Mdel P; Schroeder H F; Roizen G V; Honeyman M J; Sánchez M L
Rev Med Chil; 2006 Mar; 134(3):326-31. PubMed ID: 16676105
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
20. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
